NIH-CSR <script type="text/javascript"> var wmNotice = "UNT Web Archive - External links, forms, and search boxes may not function within this collection. Url: http://cms.csr.nih.gov/PeerReviewMeetings/CSRIRGDescription/ONCIRG/CONC.htm time: 14:27:31 Sep 20, 2008"; var wmHideNotice = "hide"; var contextRoot = "https://webarchive.library.unt.edu/eot2008/"; </script> <script type="text/javascript" src="https://webarchive.library.unt.edu/eot2008/js/disclaim.js"></script> <span id="Postingname3_PostingDisplayName">Clinical Oncology Study Section [CONC]</span> (ONCIRG)

[CONC Roster]

The Clinical Oncology Study Section reviews applications in the areas of clinical patient-oriented research and clinical therapeutic trials. This includes clinical trials with therapeutic intent using drugs, radiation, surgery, and/or biological agents.

Specific areas covered by CONC include:

Chemotherapy
Surgical oncology
Immunotherapy
Vaccine and gene therapy
Radiation therapy and radiopharmaceuticals
Combined modality therapy
Pharmacologic and toxicologic studies of new therapeutic modalities in patients
Non-behavioral alternative cancer therapies
Correlative studies relevant to therapeutic clinical trials
Trials and research on the treatment of cancer therapy-related nausea and vomiting, pain, mucositis, alopecia and fatigue
Age-specific issues including: changes in tumor behavior with aging, clinical and laboratory assessment of the older cancer patient, age-related factors that withstand effective cancer treatment, coordination of care of the older cancer patient, pharmacology of chemotherapy agents, and amelioration of toxicity.

CONC has the following shared interests within the ONC IRG:

With Cancer Immunopathology and Immunotherapy [CII] for some experimental immunotherapy studies: In general, preclinical studies could be assigned to CII and clinical studies by CONC.
With Radiation Therapeutics and Biology [RTB]: Basic and translational studies of radiotherapy (mechanisms, actions, radiobiology, etc.) could be assigned to RTB, early clinical trials and evaluations of novel therapeutic approaches could be assigned to CONC.
With Developmental Therapeutics [DT]: Preclinical and translational studies of drug activity could be assigned to DT, while clinical studies could be assigned to CONC.

CONC has the following shared interests outside the ONC IRG:

With the Genes, Genomes and Genetics [GGG] IRG: In general research relating to polymorphisms could be assigned to GGG; studies having a clinical component could be assigned to CONC.
With the Health of the Population [HOP] IRG: Epidemiological studies of cancer could be assigned to HOP, while clinical studies could be assigned to CONC.
With the Risk, Prevention and Health Behavior [RPHB] IRG: Studies of human behaviors that relate to cancer risk and the development of behavioral approaches to cancer prevention could be assigned to RPHB.
With the Immunology [IMM] IRG: There is a shared interest between IMM and ONC in the use of bone marrow to treat hematological cancers. However, clinical studies could be assigned to CONC.
With the Infectious Diseases and Microbiology [IDM] IRG: In general, clinical studies of tumor-associated viruses or other pathogens could be assigned to CONC.
With the Hematology [HEME] IRG: In general, clinical studies of hematological malignancies could be assigned to CONC.
With the Digestive Sciences [DIG] IRG: Studies of the treatment of Barrett's Esophagus and GI polyps could be assigned to DIG.
With the Surgical Sciences, Biomedical Imaging, and Bioengineering [SBIB]: Where the focus of the study is the evaluation of a radiological approach, review could be in SBIB; clinical studies of cancer diagnosis using established radiological procedures or studies focusing on therapy could be assigned to CONC.